Information  X 
Enter a valid email address

EKF Diagnostics Hldg (EKF)

  Print      Mail a friend

Friday 26 April, 2019

EKF Diagnostics Hldg

Acquisition of further interest in Renalytix AI

RNS Number : 3144X
EKF Diagnostics Holdings PLC
26 April 2019
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Acquisition of further interest in Renalytix AI plc

 

EKF Diagnostics Holdings (AIM: EKF), the AIM quoted point-of-care business, notes the announcement by Renalytix AI plc (AIM: RENX) ("RenalytixAI"), that on 26 April 2019 EKF Diagnostics plc ("EKF") acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.

 

Christopher Mills, Julian Baines and Richard Evans (Chairman, CEO and FD/COO respectively of EKF) are each directors of, and directly and indirectly shareholders in, RenalytixAI.

 

Following the above transaction, which took place at an average price of 123.5973 pence per RenalytixAI share, EKF's interest in RenalytixAI is now in 2,677,981 Ordinary Shares, representing 4.98% of RenalytixAI's issued share capital.

 

Further details of the underlying trades are disclosed in the announcement by RenalytixAI in this regard.

 

Enquiries:

 

EKF Diagnostics Holdings plc 

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 


Richard Evans, FD & COO




N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)




Walbrook PR Limited                                                                           Tel: 020 7933 8780 or [email protected] 

Paul McManus/ Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

 



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLMMGZDNVVGLZM

a d v e r t i s e m e n t